Background
There are 24 million people in the world with Treatment Resistant Schizophrenia (TRS). Clozapine is the only effective treatment for TRS but is massively underused due to risk of adverse reactions. The Myogenes Clozapine Test can minimize these risks and free up hospital beds.
Why Myogenes Clozapine Test?
Developed in collaboration with Prof. David Taylor, the clozapine genetic test is for use in the treatment of schizophrenia.
An easy to administer simple saliva test that looks at evidence based genes associated with a patient’s response to clozapine. This test is for people with schizophrenia, current Clozapine patients who cannot achieve a therapeutic level despite high dose Clozapine, patients with only a partial treatment response, patients where neutrophil counts necessitate interruption of treatment, and patients with possible benign ethnic neutropenia but their status is uncertain.
